Clinical Trial

Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.

Name: Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. — clinical trial record (NCT07274761)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To assess the efficacy and safety of sunvozertinib as neoadjuvant therapy in patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).

Trial Details

NCT Number	NCT07274761
Lead Sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Conditions	Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer
Enrollment	24 participants
Start Date	2024-10-17
Primary Completion	2030-05-01 (estimated)
Study Completion	2030-05-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-10